ANIP

ANI Pharmaceuticals ANIP is executing a clear pivot toward higher-margin specialty revenues, led by Purified Cortrophin Gel. That momentum is now showing up in earnings power and a higher 2026 outlook. The debate is whether that upside is strong enough to offset two real risks: intensifying competition in key markets and meaningful customer concentration. That tradeoff frames the rest of the setup. Cortrophin Gel has become the company’s primary growth engine, driving the Rare Disease franchise and pushing the mix toward specialty therapies. In 2025, Cortrophin delivered $347.8 million in revenue, up about 76% year over year, and management expects that strength to continue in 2026 with sales guidance of $540-$575 million. The company is also investing behind adoption, including a dedicated ~90-person sales force focused on acute gouty arthritis flares and a prefilled syringe formulation that has already become the majority of new patient starts. The key offsets are competition and concentration. In retina, the Iluvien franchise faces entrenched alternatives from larger players. AbbVie ABBV markets Ozurdex, which competes across diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment, while Regeneron Pharmaceuticals REGN remains a major force in diabetic macular edema through Eylea and Eylea HD. On the distribution side, three wholesale customers represented 53% of 2025 net revenue and 64% of accounts receivable, which can amplify pricing pressure if purchasing leverage increases. After the strong first quarter, ANI raised its full-year 2026 total net revenue outlook by $25 million to $1.08-$1.14 billion. It also lifted adjusted EBITDA guidance by $10 million to $285-$300 million and raised adjusted earnings per share to $9.19-$9.69 from $8.83-$9.34. Importantly, the company reaffirmed product-level expectations for both key branded drivers. Cortrophin Gel remained guided to $540-$575 million, and Iluvien was reaffirmed at $78-$83 million, which implies a return to growth versus 2025. Management tied the higher full-year outlook to two drivers: stronger-than-expected Generics performance exiting the first quarter and improved visibility into upcoming launches for the remainder of 2026. That combination matters because it supports the idea that the guidance raise was not solely a one-quarter timing benefit. First-quarter 2026...

Image source: The Motley Fool. Friday, May 8, 2026, 8 a.m. ET President and Chief Executive Officer — Nikhil Lalwani Senior Vice President and Chief Financial Officer — Stephen Carey Senior Vice President and Head of Rare Disease Business — Christopher Mutz Need a quote from a Motley Fool analyst? Email [email protected] Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Senior Vice President and Chief Financial Officer; and Chris Mutz, Senior Vice President and Head of ANI's Rare Disease Business. You can also access the webcast of this call through the Investors section of the ANI website at anipharmaceuticals.com. This call is accompanied by a slide deck that can be accessed by going to the Events section of the Investors page of our website. You can turn to our forward-looking statements on Slide 2. Before we begin, I would like to remind everyone that some statements we make today may be considered forward-looking statements, as defined by the Private Securities Litigation Reform Act. ANI cautions that these forward-looking statements are subject to risks and uncertainties, including those noted in our press release issued this morning and our filings with the SEC that may cause actual results to differ materially from those projected in the forward-looking statements. ANI specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law. During this call, we will also refer to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered as an alternative to financial measures required by GAAP. The non-GAAP financial measures referenced on this call are reconciled to the most directly comparable GAAP financial measures in a table available in the slide deck accompanying this call. The archived webcast will be available for 30 days on our website, anipharmaceuticals.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on May 8, 2026. Since then, ANI may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings. And with that, I'll turn the call over to Nikhil Lalwani. Nikhil Lalwani: Thank you, Irina, and welcome again to ANI. Good morning, everyone, and thank you for joining us for ANI's First Quarter 2026 Earnings C...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ANI Pharmaceuticals (NASDAQ:ANIP) and the best and worst performers in the pharmaceuticals industry. The pharmaceuticals sector develops, manufactures, and distributes drugs, benefiting from diversified portfolios of branded and generic medications. Looking ahead, growth will be driven by innovations in precision medicine, such as genetic therapies and advanced biologics, and the increasing use of AI to speed and increase the efficiency of drug discovery. These could specifically magnify the advantages of the most scaled players. Conversely, the sector faces considerable headwinds from intense, bipartisan political pressure on drug pricing, scrutiny of patent practices, and growing competition from biosimilars. These could specifically stymie the growth of smaller companies or ones facing patent expirations on key drugs. The 17 pharmaceuticals stocks we track reported a mixed Q1. As a group, revenues beat analysts’ consensus estimates by 1.5% while next quarter’s revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 5.5% since the latest earnings results. With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments. ANI Pharmaceuticals reported revenues of $237.5 million, up 20.5% year on year. This print exceeded analysts’ expectations by 14%. Overall, it was an exceptional quarter for the company with a beat of analysts’ EPS and revenue estimates. “We delivered a strong first quarter, generating $237.5 million in revenue and $63.0 million in adjusted non-GAAP EBITDA, with solid performance across all business units,” said Nikhil Lalwani, President and CEO of ANI. ANI Pharmaceuticals scored the biggest analyst estimates beat of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 5.5% sinc...

Last week's profit announcement from ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was underwhelming for investors, despite headline numbers being robust. We did some digging and found some worrying underlying problems. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow (FCF) during a given period. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'. As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth. Over the twelve months to March 2026, ANI Pharmaceuticals recorded an accrual ratio of -0.11. That indicates that its free cash flow was a fair bit more than its statutory profit. In fact, it had free cash flow of US$183m in the last year, which was a lot more than its statutory profit of US$83.9m. ANI Pharmaceuticals' free cash flow improved over the last year, which is generally good to see. Having said that, there is more to consider. We must also consider the impact of unusual items on statutory profit (and thus the accrual ratio), as well as note the ramifications of the company issuing new shares. See our latest analysis for ANI Pharmaceuticals That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. One essential aspect of assessing earnings quality is to look at how much a company is diluting shareholders. ANI Pharmaceuticals expanded the number of shares on issue by 5.9% over the last year. Therefore, each share now receives a smaller portion of profit. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company's profits, while...

ANI Pharmaceuticals ANIP delivered first-quarter 2026 adjusted EPS of $2.05, up nearly 21% year over year and well ahead of the Zacks Consensus Estimate of $1.28. Quarterly revenues totaled $237.5 million, up 20.5% from the year-ago period. The metric also beat the Zacks Consensus Estimate of $205.4 million. The quarter reflected solid execution across the portfolio, led by continued momentum for Purified Cortrophin Gel and contributions from a newly monetized intellectual property licensing arrangement. Rare Disease and Brands' total net revenues were $128.2 million, up 36% year over year, supported by contributions from both Cortrophin Gel and Iluvien. Within that bucket, Cortrophin Gel net revenues rose 42% to $75.1 million, while Iluvien sales increased 19.5% to $19.3 million. The reported Cortrophin sales marginally missed the Zacks Consensus Estimate of about $76 million. Per management, the drug’s sales were impacted primarily by seasonality tied to insurance re-verifications, which took longer to clear early in the quarter due to higher patient volume at physicians’ offices and weather-related physician office closures in some regions. ANIP's shares fell more than 2% on Friday, suggesting some investors focused on the slightly softer-than-expected Cortrophin print despite the broader earnings and revenue beat. Year to date, the stock has gained about 4% against the industry’s nearly 3% decline. Image Source: Zacks Investment Research The company also reported $21.5 million in brand royalties and other revenues in the quarter, reflecting the up-front payment and early royalty income tied to its Harmony Biosciences HRMY licensing agreement. By contrast, Brands' revenues declined 51% year over year to $12.3 million as demand normalized for certain products. In January, the company’s Novitium subsidiary entered into an agreement with Harmony Biosciences, under which ANIP out-licensed intellectual property related to pitolisant, marketed under the brand name Wakix. The agreement generated a $15 million upfront license fee and includes low single-digit royalties on sales of pitolisant-based products. It provides for an additional $10 million in development milestones that management expects to be achieved in the second and third quarters of 2026. Generics and Other net revenues were $109.2 million in the first quarter, up 6% year over year. Growth was driv...

As May began, astute investors started looking for companies demonstrating steady earnings growth as a sign of solid profitability. However, earnings acceleration is even more impactful and often serves as a stronger catalyst for driving stock prices higher. Studies indicate that top-performing stocks typically exhibit earnings acceleration before their share prices rise. To that end, ANI Pharmaceuticals, Inc. ANIP, Cummins Inc. CMI and Seadrill Limited SDRL are showing strong earnings acceleration this month. Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if a company’s quarter-over-quarter earnings growth rate increases within a stipulated time frame, it can be called earnings acceleration. In the case of earnings growth, you pay for something that is already reflected in the stock price. However, earnings acceleration helps identify stocks that haven’t yet caught investors' attention and, once secured, will invariably lead to a rally in share price. This is because earnings acceleration considers both the direction and magnitude of growth rates. An increasing percentage of earnings growth means that the company is fundamentally sound and has been on the right track for a considerable period. Meanwhile, a sideways percentage of earnings growth indicates a period of consolidation or slowdown, while a decelerating percentage of earnings growth may drag prices down. Look at stocks for which the last two quarter-over-quarter percentage EPS growth rates exceed the previous periods’ growth rates. The projected EPS growth rate for the upcoming quarter is expected to exceed that of prior periods. EPS % Projected Growth (Q1)/(Q0) greater than EPS % Growth (Q0)/(Q-1): The projected growth rate for the current quarter (Q1) over the completed quarter (Q0) has to be greater than the growth rate from the completed quarter (Q0) over one quarter ago (Q-1). EPS % Growth (Q0)/(Q-1) greater than EPS % Growth (Q-1)/(Q-2): The growth rate for the completed quarter (Q0) over one quarter ago (Q-1) has to be greater than the growth rate from one quarter ago (Q-1) over two quarters ago (Q-2). EPS % Growth (Q-1)/(Q-2) greater than EPS % Growth (Q-2)/(Q-3): The growth rate from one quarter ago (Q-1) over two quarters ago (Q-2) has to be greater than the growth rate from two quarters ago (Q-2) over three quarters ago (Q-3). In...

This article first appeared on GuruFocus. Release Date: May 08, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported a 20% year-over-year increase in total net revenues for the first quarter, driven by strong performance in both rare disease and generics businesses. The company raised its 2026 financial guidance for total revenue to a range of $1.08 billion to $1.14 billion and adjusted EBITDA to a range of $285 million to $300 million. Clotrophin Gel, a lead rare disease asset, saw a 42% year-over-year increase in net revenues, with strong momentum in new patient starts and monthly volumes dispensed. ANI Pharmaceuticals Inc (NASDAQ:ANIP) entered into a licensing transaction with Harmony Biosciences, receiving a $15 million upfront license fee and potential for additional milestone payments and royalties. The company launched six new generics products year-to-date and maintained its position as the number two player in overall CGT approvals. Non-GAAP gross margin decreased by approximately 230 basis points from the prior-year period, primarily due to higher sales of royalty-bearing products. Insurance re-verifications took longer to clear in the first quarter, impacting Cortrophin Gel's performance due to seasonality and weather-related physician office closures. Non-GAAP selling, general, and administrative expenses increased by 12% due to initial marketing and recruitment expenses for organizational expansion. The company faces ongoing Medicare market access challenges for its retina franchise, impacting Alluvian sales. Despite strong first-quarter results, the company anticipates only modest sequential growth for Alluvian throughout the year. Warning! GuruFocus has detected 6 Warning Signs with MGLUY. Is ANIP fairly valued? Test your thesis with our free DCF calculator. Q: Can you discuss the growth sources for Cortrophin, particularly in non-gout settings like pulmonology and ophthalmology, and the dynamics of vials and treatment duration across various indications? Also, how might payer access evolve as your footprint grows, especially in gout? A: The growth is primarily from core indications such as rheumatology, nephrology, neurology, pulmonology, and ophthalmology. The gout expansion will have a more significant impact in 2027. Vials and treatment dura...

(Updates with share buyback program and stock movement in the last two paragraphs.) ANI Pharmaceu

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares surged 9.88% in premarket trading on Friday after the specialty drugmaker reported first-quarter results that exceeded analyst expectations and raised its full-year guidance. The company posted adjusted earnings per share of $2.05, well above the Wall Street consensus estimate of $1.45 per share. Quarterly revenue increased 20.5% year-on-year to $237.5 million, beating analyst forecasts of $213.42 million. ANI said the strong quarter was supported by broad-based growth across its business divisions, with particularly strong performance from its lead product Cortrophin Gel. Revenue from Cortrophin Gel climbed 42.1% from a year earlier to $75.1 million during the quarter. Following the stronger-than-expected results, ANI increased its fiscal 2026 revenue outlook to a range of $1.08 billion to $1.14 billion. The midpoint of the updated forecast, $1.11 billion, sits slightly above analyst expectations of $1.09 billion. The company also lifted its adjusted earnings per share guidance to between $9.19 and $9.69, with the midpoint of $9.44 exceeding the current consensus estimate of $9.07. Adjusted EBITDA guidance was also increased to a range of $285 million to $300 million, compared with the prior forecast of $275 million to $290 million. “We delivered a strong first quarter, generating $237.5 million in revenue and $63.0 million in adjusted non-GAAP EBITDA, with solid performance across all business units,” said Nikhil Lalwani, President and CEO. ANI’s Rare Disease segment generated revenue of $94.4 million during the quarter, representing growth of 36.9% compared with the same period last year. Revenue from ILUVIEN increased 19.5% year-on-year to $19.3 million. Meanwhile, sales of generic pharmaceutical products rose 6.8% to $105.4 million, supported by new product launches. Brand royalties and other revenue totalled $21.5 million, including a $15.0 million upfront payment related to a licensing agreement with Harmony Biosciences. The company also announced that its board of directors approved a new $100 million share repurchase programme running through May 2029. ANI Pharmaceuticals stock price

Interested in ANI Pharmaceuticals, Inc.? Here are five stocks we like better. ANI reported Q1 net revenue of $237.5 million (+20% YoY), adjusted non‑GAAP EBITDA of $63 million (+24%) and adjusted EPS of $2.05, and raised full‑year 2026 guidance to net revenue $1.08–1.14 billion, adjusted EBITDA $285–300 million and adjusted EPS $9.19–9.69. Rare‑disease brands led performance: Cortrophin Gel net revenue was $75.1 million (+42% YoY) with expansion into an under‑penetrated gout opportunity and a new commercial team, while ILUVIEN grew to $19.3 million (+20%) with upcoming phase IV data expected in Q3 2026. ANI recognized $21.5 million in Q1 revenue from a pitolisant licensing deal with Harmony (including a $15 million upfront fee) with a potential $10 million milestone, authorized a $100 million share buyback program, and finished the quarter with $311.2 million cash and $625 million of debt (net leverage ~1.3x). ANI Pharmaceuticals (NASDAQ:ANIP) reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease company,” led by growth in Cortrophin Gel and ILUVIEN, contributions from a new intellectual property licensing transaction with Harmony Biosciences, and steady generics performance. Total net revenue rose 20% year over year to $237.5 million, while adjusted non-GAAP EBITDA increased 24% to $63 million, Chief Financial Officer Stephen Carey said. Adjusted non-GAAP diluted EPS was $2.05, up from $1.70 a year earlier. Following the quarter, the company raised its full-year 2026 guidance for total net revenue and adjusted EBITDA. → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% President and CEO Nikhil Lalwani said Cortrophin Gel net revenue was $75.1 million in the first quarter, up 42% year over year, and “consistent with the expectations we outlined during our last quarterly call.” Chris Mutz, SVP and head of Rare Disease, said performance reflected typical first-quarter seasonality tied to insurance reverifications, which “took slightly longer to clear in January and February,” partly due to increased volume in physician offices and weather-related closures in some areas. As those reverifications cleared, Mutz said sales accelerated in February and March and carried into April. Lalwani added that April produced “the highest number of new patien...

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.7 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +60.16%. A quarter ago, it was expected that this drugmaker would post earnings of $1.99 per share when it actually produced earnings of $2.33, delivering a surprise of +17.09%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. ANI, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $237.46 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 15.61%. This compares to year-ago revenues of $197.12 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. ANI shares have added about 6.3% since the beginning of the year versus the S&P 500's gain of 7.2%. While ANI has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for ANI was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks...

ANI Pharmaceuticals (ANIP) reported Q1 adjusted earnings Friday of $2.05 per diluted share, up from